ADMA Biologics Inc vs Byrna Technologies Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Byrna Technologies Inc trades at $4.66 (market cap $109.84M). The key difference: ADMA Biologics Inc is far larger — about 19.8× Byrna Technologies Inc's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, Byrna Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | BYRN | |
|---|---|---|
Market Cap | $2.18B | $109.84M |
Sector | Health | Technology |
52-Week High | $20.38 | $27.63 |
52-Week Low | $7.60 | $3.18 |
Enterprise Value | $2.25B | $101.44M |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
BYRN trades at $4.45, up 2.06% today, but faces bearish technical signals and recent earnings challenges. The company reported a Q2 2026 loss of $0.44 per share, missing estimates, with revenue declining 42.5% year-over-year. Despite a 71.4% analyst buy rating, negative net income margin and cash flow concerns highlight operational headwinds. Recent management appointments aim to revitalize marketing and retail growth.
Outlook remains cautious due to weak sales trends and profitability issues, though strategic hires and acquisitions could support a turnaround. Key risks include sustained revenue declines and competitive pressures. Investors should weigh analyst optimism against fundamental weaknesses before considering a position.
Trailing returns across standard periods
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →